pomalidomide
E854983
antineoplastic agent
immunomodulatory drug
orphan drug
pharmaceutical drug
small molecule
thalidomide analogue
Pomalidomide is an immunomodulatory drug used primarily to treat multiple myeloma, designed as a more potent and safer derivative of thalidomide.
Statements (79)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
immunomodulatory drug ⓘ orphan drug ⓘ pharmaceutical drug ⓘ small molecule ⓘ thalidomide analogue ⓘ |
| affectsPathway | ubiquitin–proteasome pathway ⓘ |
| belongsToClass |
IMiDs
NERFINISHED
ⓘ
immunomodulatory imide drugs ⓘ |
| decreasesCytokine | TNF-alpha ⓘ |
| developedAs |
more potent derivative of thalidomide
ⓘ
safer derivative of thalidomide ⓘ |
| hasAdverseEffect |
anemia
ⓘ
constipation ⓘ diarrhea ⓘ fatigue ⓘ increased risk of venous thromboembolism ⓘ neutropenia ⓘ peripheral neuropathy ⓘ thrombocytopenia ⓘ |
| hasATCCode | L04AX06 NERFINISHED ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBoxedWarningFor |
embryo-fetal toxicity
ⓘ
venous and arterial thromboembolism ⓘ |
| hasCASNumber | 19171-19-8 ⓘ |
| hasChemicalClass |
glutarimide derivative
ⓘ
phthalimide derivative ⓘ |
| hasChemicalFormula | C13H11N3O4 ⓘ |
| hasDosingSchedule | 21 days on, 7 days off per 28-day cycle ⓘ |
| hasEliminationHalfLife | approximately 7.5 hours ⓘ |
| hasEMAAuthorizationYear | 2013 ⓘ |
| hasFDAApprovalYear | 2013 ⓘ |
| hasIndication |
AIDS-related Kaposi sarcoma
ⓘ
Kaposi sarcoma in HIV-negative patients ⓘ refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| hasIUPACName | 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione ⓘ |
| hasLegalStatusInEU | prescription only ⓘ |
| hasLegalStatusInUS | prescription only ⓘ |
| hasMechanismOfAction |
antiangiogenic activity
ⓘ
direct antitumor activity ⓘ immunomodulation ⓘ inhibition of cytokine production ⓘ |
| hasMolarMass | 273.24 g/mol ⓘ |
| hasPregnancyCategory | X (contraindicated in pregnancy) ⓘ |
| hasPregnancyPreventionRequirement | yes ⓘ |
| hasPrimaryIndication | multiple myeloma ⓘ |
| hasProteinBinding | 12–44% ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStereochemistry | racemic mixture ⓘ |
| hasSynonym |
Actimid
NERFINISHED
ⓘ
CC-4047 NERFINISHED ⓘ |
| hasTradeName |
Imnovid
NERFINISHED
ⓘ
Pomalyst NERFINISHED ⓘ |
| hasTypicalDose | 4 mg once daily in 28-day cycles ⓘ |
| hasUNIID | 27O7W4T232 ⓘ |
| increasesCytokine |
interferon-gamma
ⓘ
interleukin-2 ⓘ |
| isAdministeredAs | oral capsule ⓘ |
| isChiral | yes ⓘ |
| isContraindicatedIn | pregnancy ⓘ |
| isDerivativeOf | thalidomide NERFINISHED ⓘ |
| isExcretedVia |
feces
ⓘ
urine ⓘ |
| isMetabolizedBy |
CYP1A2
NERFINISHED
ⓘ
CYP2C19 NERFINISHED ⓘ CYP3A4 NERFINISHED ⓘ |
| isSubjectTo | REMS program NERFINISHED ⓘ |
| isTeratogenic | true ⓘ |
| isUsedForPatients |
who have received at least two prior therapies for multiple myeloma
ⓘ
whose disease progressed on or within 60 days of completion of last therapy ⓘ |
| modulatesImmuneCells |
NK cells
ⓘ
T cells NERFINISHED ⓘ |
| molecularTarget | cereblon NERFINISHED ⓘ |
| requiresRiskManagementProgram | yes ⓘ |
| usedInCombinationWith | dexamethasone NERFINISHED ⓘ |
| wasApprovedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| wasDevelopedBy | Celgene NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.